Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

Product portfolio
Potentially strong market reviews
Competitive analytics
Prospect partners
Mergers and acquisitions project data
Latest trends across a particular industry area
Research and development strategies
The analysis of new customers
A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853

Sort by:

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 3,500.00

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Neuronal Acetylcholi...

May 2022 48 pages

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 3,500.00

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the r...

May 2022 35 pages

Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,000.00

Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipel...

May 2022 163 pages

Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,000.00

Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pi...

May 2022 47 pages

Premature Labor (Tocolysis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,000.00

Premature Labor (Tocolysis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pi...

May 2022 84 pages

Pseudomonas aeruginosa Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,000.00

Pseudomonas aeruginosa Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disea...

May 2022 34 pages

Pulmonary Arterial Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,500.00

Pulmonary Arterial Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare diseas...

May 2022 370 pages

Pyelonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,000.00

Pyelonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide...

May 2022 70 pages

Rhinovirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,000.00

Rhinovirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline...

May 2022 83 pages

Somatostatin Receptor Type 4 (SSTR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 3,500.00

Somatostatin Receptor Type 4 (SSTR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Somatostatin Receptor Type 4 (SSTR4) pi...

May 2022 36 pages

Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,500.00

Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide...

May 2022 581 pages

Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

US$ 2,500.00

Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline gui...

May 2022 226 pages

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development ...

May 2022 54 pages

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

... players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) development ...

May 2022 38 pages

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

... and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and ...

May 2022 64 pages

Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) development ...

May 2022 44 pages

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development ...

May 2022 56 pages

1 Phosphatidylinositol 3 Phosphate 5 Kinase (FYVE Finger Containing Phosphoinositide Kinase or Phosphatidylinositol 3 Phosphate 5 Kinase Type III or PIKFYVE or EC 2.7.1.150) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

1 Phosphatidylinositol 3 Phosphate 5 Kinase (FYVE Finger Containing Phosphoinositide Kinase or Phosphatidylinositol 3 Phosphate 5 Kinase Type III or PIKFYVE or EC 2.7.1.150) Drugs in Development by Th...

May 2022 40 pages

3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 73 pages

3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 (5 Alpha SR2 or Steroid 5 Alpha Reductase 2 or Type II 5 Alpha Reductase or SR Type 2 or SRD5A2 or EC 1.3.1.22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 (5 Alpha SR2 or Steroid 5 Alpha Reductase 2 or Type II 5 Alpha Reductase or SR Type 2 or SRD5A2 or EC 1.3.1.22) Drugs in Development by Therapy Areas and Indica...

May 2022 37 pages

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) Drugs in Development...

May 2022 36 pages

Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA...

May 2022 86 pages

Alpha 1A Adrenergic Receptor (Alpha 1A Adrenoreceptor or Alpha 1C Adrenergic Receptor or Alpha Adrenergic Receptor 1c or ADRA1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Alpha 1A Adrenergic Receptor (Alpha 1A Adrenoreceptor or Alpha 1C Adrenergic Receptor or Alpha Adrenergic Receptor 1c or ADRA1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA...

May 2022 39 pages

Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexi...

May 2022 149 pages

Angiotensin Converting Enzyme 2 (ACE Related Carboxypeptidase or Metalloprotease MPROT15 or Angiotensin Converting Enzyme Homolog or ACE2 or EC 3.4.17.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Angiotensin Converting Enzyme 2 (ACE Related Carboxypeptidase or Metalloprotease MPROT15 or Angiotensin Converting Enzyme Homolog or ACE2 or EC 3.4.17.23) Drugs in Development by Therapy Areas and Ind...

May 2022 50 pages

Apelin Receptor (Angiotensin Receptor Like 1 or G Protein Coupled Receptor APJ or G Protein Coupled Receptor HG11 or APLNR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Apelin Receptor (Angiotensin Receptor Like 1 or G Protein Coupled Receptor APJ or G Protein Coupled Receptor HG11 or APLNR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mol...

May 2022 41 pages

Apoptosis Associated Speck Like Protein Containing A CARD (Caspase Recruitment Domain Containing Protein 5 or PYD And CARD Domain Containing Protein or Target Of Methylation Induced Silencing 1 or ASC or PYCARD) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Apoptosis Associated Speck Like Protein Containing A CARD (Caspase Recruitment Domain Containing Protein 5 or PYD And CARD Domain Containing Protein or Target Of Methylation Induced Silencing 1 or ASC...

May 2022 40 pages

ATP Binding Cassette Sub Family G Member 2 (Breast Cancer Resistance Protein or Mitoxantrone Resistance Associated Protein or Placenta Specific ATP Binding Cassette Transporter or Urate Exporter or CD338 or ABCG2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

ATP Binding Cassette Sub Family G Member 2 (Breast Cancer Resistance Protein or Mitoxantrone Resistance Associated Protein or Placenta Specific ATP Binding Cassette Transporter or Urate Exporter or CD...

May 2022 37 pages

ATP Sensitive Inward Rectifier Potassium Channel 11 (Potassium Channel Inwardly Rectifying Subfamily J Member 11 or Inward Rectifier Potassium Channel Kir6.2 or KCNJ11) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

ATP Sensitive Inward Rectifier Potassium Channel 11 (Potassium Channel Inwardly Rectifying Subfamily J Member 11 or Inward Rectifier Potassium Channel Kir6.2 or KCNJ11) Drugs in Development by Therapy...

May 2022 35 pages

ATP Sensitive Inward Rectifier Potassium Channel 8 (Inward Rectifier K(+) Channel Kir6.1 or Potassium Channel Inwardly Rectifying Subfamily J Member 8 or uKATP 1 or KCNJ8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

ATP Sensitive Inward Rectifier Potassium Channel 8 (Inward Rectifier K(+) Channel Kir6.1 or Potassium Channel Inwardly Rectifying Subfamily J Member 8 or uKATP 1 or KCNJ8) Drugs in Development by Ther...

May 2022 35 pages

Atrial Natriuretic Peptide Receptor 1 (Atrial Natriuretic Peptide Receptor Type A or Guanylate Cyclase A or NPR1 or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Atrial Natriuretic Peptide Receptor 1 (Atrial Natriuretic Peptide Receptor Type A or Guanylate Cyclase A or NPR1 or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 44 pages

Atrial Natriuretic Peptide Receptor 2 (Atrial Natriuretic Peptide Receptor Type B or Guanylate Cyclase B or NPR2 or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Atrial Natriuretic Peptide Receptor 2 (Atrial Natriuretic Peptide Receptor Type B or Guanylate Cyclase B or NPR2 or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 39 pages

Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3)...

May 2022 35 pages

B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Drugs in Development by The...

May 2022 39 pages

Baculoviral IAP Repeat Containing Protein 2 (C IAP1 or IAP Homolog B or Inhibitor Of Apoptosis Protein 2 or RING Finger Protein 48 or TNFR2 TRAF Signaling Complex Protein 2 or BIRC2 or EC 6.3.2.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Baculoviral IAP Repeat Containing Protein 2 (C IAP1 or IAP Homolog B or Inhibitor Of Apoptosis Protein 2 or RING Finger Protein 48 or TNFR2 TRAF Signaling Complex Protein 2 or BIRC2 or EC 6.3.2.) Drug...

May 2022 36 pages

Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Drugs in Develo...

May 2022 42 pages

Bile Acid Receptor (Farnesoid X Activated Receptor or Farnesol Receptor HRR 1 or Nuclear Receptor Subfamily 1 Group H Member 4 or Retinoid X Receptor Interacting Protein 14 or FXR or NR1H4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Bile Acid Receptor (Farnesoid X Activated Receptor or Farnesol Receptor HRR 1 or Nuclear Receptor Subfamily 1 Group H Member 4 or Retinoid X Receptor Interacting Protein 14 or FXR or NR1H4) Drugs in D...

May 2022 63 pages

C-C Chemokine Receptor Type 8 (CC Chemokine Receptor CHEMR1 or CMKBRL2 or Chemokine Receptor Like 1 or GPR CY6 or TER1 or CDw198 or CCR8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

C-C Chemokine Receptor Type 8 (CC Chemokine Receptor CHEMR1 or CMKBRL2 or Chemokine Receptor Like 1 or GPR CY6 or TER1 or CDw198 or CCR8) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 44 pages

C-C Motif Chemokine 2 (HC11 or Monocyte Chemoattractant Protein 1 or Monocyte Chemotactic And Activating Factor or MCAF or Monocyte Chemotactic Protein 1 or Monocyte Secretory Protein JE or Small Inducible Cytokine A2 or CCL2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

C-C Motif Chemokine 2 (HC11 or Monocyte Chemoattractant Protein 1 or Monocyte Chemotactic And Activating Factor or MCAF or Monocyte Chemotactic Protein 1 or Monocyte Secretory Protein JE or Small Indu...

May 2022 37 pages

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Rece...

May 2022 61 pages

Calpain 1 Catalytic Subunit (Calcium Activated Neutral Proteinase 1 or Calpain Mu Type or Calpain 1 Large Subunit or Cell Proliferation Inducing Gene 30 Protein or Micromolar Calpain or CAPN1 or EC 3.4.22.52) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calpain 1 Catalytic Subunit (Calcium Activated Neutral Proteinase 1 or Calpain Mu Type or Calpain 1 Large Subunit or Cell Proliferation Inducing Gene 30 Protein or Micromolar Calpain or CAPN1 or EC 3....

May 2022 38 pages

Calpain 2 Catalytic Subunit (Calcium Activated Neutral Proteinase 2 or Calpain M Type or Calpain Large Polypeptide L2 or Calpain 2 Large Subunit or Millimolar Calpain or CANPL2 or CAPN2 or EC 3.4.22.53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calpain 2 Catalytic Subunit (Calcium Activated Neutral Proteinase 2 or Calpain M Type or Calpain Large Polypeptide L2 or Calpain 2 Large Subunit or Millimolar Calpain or CANPL2 or CAPN2 or EC 3.4.22.5...

May 2022 41 pages

CD27 Antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CD27 Antigen (CD27L Receptor or T Cell Activation Antigen CD27 or Tumor Necrosis Factor Receptor Superfamily Member 7 or T14 or TNFRSF7 or CD27) Drugs in Development by Therapy Areas and Indications,...

May 2022 39 pages

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drugs in Development by Therapy Areas and Indications, Stage...

May 2022 49 pages

Cells Expressing B Cell Receptor CD22 (B Lymphocyte Cell Adhesion Molecule or Sialic Acid Binding Ig Like Lectin 2 or T Cell Surface Antigen Leu 14 or CD22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing B Cell Receptor CD22 (B Lymphocyte Cell Adhesion Molecule or Sialic Acid Binding Ig Like Lectin 2 or T Cell Surface Antigen Leu 14 or CD22) Drugs in Development by Therapy Areas and I...

May 2022 118 pages

Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Drugs in D...

May 2022 159 pages

Cells Expressing Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 40 pages

Cells Expressing C Type Lectin Domain Family 12 Member A (Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic Cell Associated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing C Type Lectin Domain Family 12 Member A (Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic Cell Associated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A) Drugs in Dev...

May 2022 54 pages

Cells Expressing Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drugs in Development by Therapy Areas and Indic...

May 2022 59 pages

Cells Expressing CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drugs in Development by Therapy Areas and I...

May 2022 40 pages